Table 1.
Prevalence of persistence of at least a 1/10 amount of A/H5N1 antibodies and seroconversion (≥4 times higher levels compared to baseline) among participants
| Time | Persistence of at least a 1/10 amount of antibodies, n (%) | Seroconversion (≥4 times higher than baseline), n (%) | Geometric mean titer1 | Geometric mean titer ratio1 |
|---|---|---|---|---|
| Baseline2 | 11 (12.8) | - | 5.6 | 1.0 |
| 21 d after full vaccination (42 d after the first dose) | 86 (100) | 81 (92.4) | 66.8 | 11.8 |
| 30 mo3 | 73 (84.9) | 49 (57.0) | 22.3 | 4.0 |
| 36 mo3 | 45 (52.3) | 26 (30.2) | 12.0 | 2.1 |
1
Immunological indicators.
2
Before receiving the IVACFLU-A/H5N1 vaccine.
3
At 30 months and 36 months after receiving both IVACFLU-A/H5N1 vaccines – full vaccination.